

Cover image: The effect of anti-GM-CSF antibodies on the cartilage layers of the patella and femur of IL-17R<sup>-/-</sup> mice

## Editor

Tore K Kvien

## Associate Editors

Francis Berenbaum

Hans Bijlsma

Dimitrios Boumpas

Gerd Burmester

Mary Crow

Iain McInnes

## Editorial office

Annals of the Rheumatic Diseases

BMJ Publishing Group Ltd

BMA House

Tavistock Square

London WC1H 9JR, UK

T: +44 (0)20 7383 6250

F: +44 (0)20 7383 6668

E: [ard@bmj.com](mailto:ard@bmj.com)

ISSN: 0003-4967 (print)

ISSN: 1468-2060 (online)

Impact Factor: 6.411

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2009 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission. ARD is published by BMJ Publishing Group Ltd, typeset by The Charlesworth Group and printed in the UK on acid-free paper from sustainable forests by Cambrian Printers Limited, Aberystwyth, UK.

*Annals of the Rheumatic Diseases* (USPS No: 002-152) is published monthly by BMJ Publishing Group and distributed in the USA by SPP, 75 Aberdeen Road, Emigsville, PA 17318, USA. Periodicals postage paid at Emigsville, PA, USA. POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, PO Box 437, Emigsville, PA 17318-0437, USA.

## Editorial

- 609** Immune–endothelial–nerve interaction: an explanation for the failure of the gastrointestinal system in systemic sclerosis?  
*M Matucci-Cerinic, L Czirják*

## Review

- 611** A systematic review of ultrasonography in osteoarthritis  
*H I Keen, R J Wakefield, P G Conaghan*

## Recommendations

- 620** EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)  
*O Kowal-Bielecka, R Landewé, J Avouac, S Chwiesko, I Miniati, L Czirják, P Clements, C Denton, D Farge, K Fligelstone, I Földvari, D E Furst, U Müller-Ladner, J Seibold, R M Silver, K Takehara, B Garay Toth, A Tyndall, G Valentini, F van den Hoogen, F Wigley, F Zulian, Marco Matucci-Cerinic, and the EUSTAR co-authors*

- 629** European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research  
*J Avouac, O Kowal-Bielecka, R Landewé, S Chwiesko, I Miniati, L Czirják, P Clements, C Denton, D Farge, K Fligelstone, I Földvari, D E Furst, U Müller-Ladner, J Seibold, R M Silver, K Takehara, B Garay Toth, A Tyndall, G Valentini, F van den Hoogen, F Wigley, F Zulian, M Matucci-Cerinic, and EUSTAR coauthors*

## Clinical and epidemiological research

- 635** Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register  
*F H M Prince, M Twilt, R ten Cate, M A J van Rossum, W Armbrust, E P A H Hoppenreijis, M van Santen-Hoeufft, Y Koopman-Keemink, N M Wulffraat, L W A van Suijlekom-Smit*

- 642** Long-term outcome following total knee arthroplasty: a controlled longitudinal study  
*J Cushnaghan, J Bennett, I Reading, P Croft, P Byng, K Cox, P Dieppe, D Coggon, C Cooper*

- 648** Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register  
*J Askling, E Baecklund, F Granath, P Geborek, M Fored, C Backlin, L Bertilsson, L Cöster, L T Jacobsson, S Lindblad, J Lysholm, S Rantapää-Dahlqvist, T Saxne, R van Vollenhoven, L Klareskog, N Fehelius*

- 654** Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab  
*M Hirao, J Hashimoto, H Tsuboi, A Nampei, H Nakahara, N Yoshio, T Mima, H Yoshikawa, N Nishimoto*

- 658** Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients  
*C Charlier, C Henegar, O Launay, C Pagnoux, A Berezne, B Bienvenu, P Cohen, L Mouthon, L Guillevin*

- 664** Familial aggregation of psoriatic arthritis  
*V Chandran, C T Schentag, J E Brockbank, F J Pellett, S Shanmugarajah, S M A Toloza, P Rahman, D D Gladman*

- 668** The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs  
*M W van der Linden, S van der Bij, P Welsing, E J Kuipers, R M C Herings*

- 674** One year change of knee cartilage morphology in the first release of participants from the Osteoarthritis Initiative progression subcohort: association with sex, body mass index, symptoms and radiographic osteoarthritis status  
*F Eckstein, S Maschek, W Wirth, M Hudelmaier, W Hitzl, B Wyman, M Nevitt, M-P Hellio Le Graverand, the OAI Investigator Group*

- 680** Measuring quality of care for rheumatic diseases using an electronic medical record  
*J C Agnew-Blais, J S Coblyn, J N Katz, R J Anderson, J Mehta, D H Solomon*

- 685** Work disability and health-related quality of life in males and females with psoriatic arthritis  
*M Wallenius, J F Skomsvoll, W Koldingsnes, E Rodevand, K Mikkelsen, C Kaufmann, T K Kvien*

- 690** Investigating the determinants of international differences in the prevalence of chronic widespread pain: evidence from the European Male Ageing Study  
*G J Macfarlane, S R Pye, J D Finn, F C W Wu, A J Silman, G Bartfai, S Boonen, F Casanueva, G Forti, A Giwerzman, T S Han, I T Huhtaniemi, K Kula, M E J Lean, T W O'Neill, N Pendleton, M Punab, D Vanderschueren, and the EMAS Study Group*

- 696** Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study  
*M Rudwaleit, E Rodevand, P Holck, J Vanhoof, M Kron, S Kary, H Kupper*

## MORE CONTENTS ►



This article has been chosen by the editor to be of special interest or importance and is freely available online.



Articles carrying the Unlocked Logo are freely available online under the BMJ Journals unlocked scheme. See <http://ard.bmj.com/info/unlocked.dtl>

C O P E COMMITTEE ON PUBLICATION ETHICS

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

[www.publicationethics.org.uk](http://www.publicationethics.org.uk)



When you have finished with this please recycle it

- 702** Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)  
*P J Mease, P Ory, J T Sharp, C T Ritchlin, F Van den Bosch, F Wellborne, C Birbara, G T D Thomson, R J Perdok, J Medich, R L Wong, D D Gladman*

### Basic and translational research

- 710** Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract dysmotility  
*Y Kawaguchi, Y Nakamura, I Matsumoto, E Nishimagi, T Satoh, M Kuwana, T Sumida, M Hara*
- 715** Analysis of C1q polymorphisms suggests association with systemic lupus erythematosus, serum C1q and CH50 levels and disease severity  
*H A Martens, M W Zuurman, A H M de Lange, I M Nolte, G van der Steege, G J Navis, C G M Kallenberg, M A Seelen, M Bijl*
- 721** Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor  $\alpha$ -independent mouse model  
*C Plater-Zyberk, L A B Joosten, M M A Helsen, M I Koenders, P A Baeuerle, W B van den Berg*
- 729** B cell epitopes of the heterogeneous nuclear ribonucleoprotein A2: identification of a new specific antibody marker for active lupus disease  
*G Schett, H Dumortier, E Hoefler, S Muller, G Steiner*
- 736** Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles  
*O Snir, M Widhe, C von Spee, J Lindberg, L Padyukov, K Lundberg, Å Engström, P J Venables, J Lundeberg, R Holmdahl, L Klareskog, V Malmström*


- 744** Activated CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells inhibit osteoclastogenesis and collagen-induced arthritis  
*H Kelchtermans, L Geboes, T Mitera, D Huskens, G Leclercq, P Matthys*
- 751** Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor  $\alpha$  therapy in rheumatoid arthritis  
*J D Cañete, R Celis, C Moll, E Izquierdo, S Marsal, R Sanmartí, A Palacín, D Lora, J de la Cruz, J L Pablos*

### Letters

- 757** HLA-B27 sequences identified in a mediaeval skeleton with ankylosing spondylitis  
*I Leden, A Götherström, L Drenzel, B Svensson*
- 758** Thiopurinemethyltransferase (TPMT) genotype and TPMT activity in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: relation to azathioprine maintenance treatment and adverse effects  
*P M Stassen, R P H Derks, C G M Kallenberg, C A Stegeman*
- 759** Long-term efficacy of infliximab treatment for AA-amyloidosis secondary to chronic inflammatory arthritis  
*T Keersmaekers, K Claes, D R Kuypers, K de Vlam, P Verschuere, R Westhovens*
- 761** Long-term efficacy and toxicity of ciclosporin A in combination with methotrexate in poor prognosis rheumatoid arthritis  
*V Bejarano, P G Conaghan, S M Proudman, M H Buch, A K Brown, P Emery*
- 763** Enhanced expression of mRNA for Krüppel-like factor 5 in CD34<sup>+</sup> cells of the bone marrow in rheumatoid arthritis  
*S Hirohata, Y Miura, T Tomita, H Yoshikawa*

### Miscellaneous

- 764** Corrections



**Take the pain out of research every month**

Annals of the Rheumatic Diseases is the premier clinical rheumatology journal in Europe with an impressive impact factor of 6.411, so you'll want the guarantee of reading it every month.

Why not recommend the journal to your librarian or better still, obtain your own personal subscription? You will receive a paper copy every month as well as online access for just £227 a year (€306, \$443). Too much paper on your desk already? An online subscription is just £106 (€143, \$207).

Visit [group.bmj.com/group/subs-sales](http://group.bmj.com/group/subs-sales) - your subscription to this first class journal is just a few clicks away.

[ard.bmj.com](http://ard.bmj.com) BMJ Journals